Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;14(2):129-33.
doi: 10.1007/s40258-015-0200-7.

The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling

George A K van Voorn  1 , Pepijn Vemer  2   3 , Dominique Hamerlijnck  4 , Isaac Corro Ramos  5 , Geertruida J Teunissen  4   6 , Maiwenn Al  5 , Talitha L Feenstra  3   7
Affiliations

The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling

George A K van Voorn et al. Appl Health Econ Health Policy. 2016 Apr.

Abstract

Evaluations of healthcare interventions, e.g. new drugs or other new treatment strategies, commonly include a cost-effectiveness analysis (CEA) that is based on the application of health economic (HE) models. As end users, patients are important stakeholders regarding the outcomes of CEAs, yet their knowledge of HE model development and application, or their involvement therein, is absent. This paper considers possible benefits and risks of patient involvement in HE model development and application for modellers and patients. An exploratory review of the literature has been performed on stakeholder-involved modelling in various disciplines. In addition, Dutch patient experts have been interviewed about their experience in, and opinion about, the application of HE models. Patients have little to no knowledge of HE models and are seldom involved in HE model development and application. Benefits of becoming involved would include a greater understanding and possible acceptance by patients of HE model application, improved model validation, and a more direct infusion of patient expertise. Risks would include patient bias and increased costs of modelling. Patient involvement in HE modelling seems to carry several benefits as well as risks. We claim that the benefits may outweigh the risks and that patients should become involved.

PubMed Disclaimer

References

    1. Kristensen FB, Mäkelä M, Neikter SA, Rehnqvist N, Håheim LL, Mørland B, et al. European network for Health Technology Assessment, EUnetHTA: planning, development, and implementation of a sustainable European network for Health Technology Assessment. Int J Technol Assess Health Care. 2009;25(S2):107–116. doi: 10.1017/S0266462309990754. - DOI - PubMed
    1. Hall PS, McCabe C, Brown JM, Cameron DA. Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer. 2010;46:2674–2680. doi: 10.1016/j.ejca.2010.06.122. - DOI - PubMed
    1. Franken M, Le Polain M, Cleemput I, Koopmanschap M. Similarities and differences between five European drug reimbursement systems. Int J Technol Assess Health Care. 2013;28(4):349–357. doi: 10.1017/S0266462312000530. - DOI - PubMed
    1. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold. PharmacoEconomics. 2008;26:733–744. doi: 10.2165/00019053-200826090-00004. - DOI - PubMed
    1. Vemer P, Van Voorn GAK, Corro Ramos I, Krabbe PFM, Al M, Feenstra T. Improving model validation in HTA: comments on the guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force. Value Health. 2013;16(6):1106–1107. doi: 10.1016/j.jval.2013.06.015. - DOI - PubMed

MeSH terms

LinkOut - more resources